Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Lunsumio Market Expansion From $ Billion In 2026 To $ Billion In 2030
The historic expansion was driven by a higher incidence of non-Hodgkin lymphoma, a scarcity of effective treatments for relapsed follicular lymphoma, intensified clinical trial work in oncology, progress in antibody engineering methods, and the regulatory clearance of innovative immunotherapies.
The expansion of personalized cancer treatment strategies, the increasing use of immuno-oncology combinations, heightened investments in oncology biologics, a growing preference for outpatient cancer therapies, and ongoing advancements in bispecific antibody platforms are fueling growth during the forecast period. Key trends shaping this period include a greater uptake of bispecific antibody treatments, a stronger emphasis on T-cell engaging immunotherapies, wider application of precision oncology approaches, the development of targeted therapies for relapsed lymphomas, and improved incorporation of biomarker-driven patient selection.
Download A Free Sample Report For Comprehensive Market Insights:
Lunsumio Market Demand Drivers Creating New Revenue Opportunities
The growing incidence of blood cancer is anticipated to boost the expansion of the lunsumio market moving forward. Blood cancer is a condition that impacts the generation and role of blood cells, typically arising in the bone marrow or lymphatic system. Common varieties include leukemia, lymphoma, and myeloma. This rise in blood cancer cases can be linked to an aging population, hereditary factors, exposure to environmental hazards, compromised immune systems, lifestyle decisions, and enhanced diagnostic methods. Lunsumio, or mosunetuzumab, functions as a bispecific antibody designed to combat blood cancers like lymphoma by attaching to both malignant B cells and T cells, thereby enabling the immune response to eliminate cancer cells. It proves beneficial in controlling diseases with high blood cancer rates, providing a therapeutic alternative for patients with relapsed or hard-to-treat conditions. For example, according to the American Cancer Society, a non-profit cancer advocacy organization based in the US, leukemia cases in 2024 rose to 62,770, an uptick from 59,610 reported in 2023. Consequently, the escalating prevalence of blood cancer is fueling the growth of the lunsumio market.
Lunsumio Market Segment Analysis: What Are The Major Market Categories?
The lunsumio market covered in this report is segmented –
1) By Formulation: Injectable Formulation (Intravenous), Pre-Filled Syringes
2) By Indication: Treatment Of Relapsed Or Refractory FL, Treatment Of Other Non-Hodgkin Lymphomas
3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients With High-Risk Disease Profiles
4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Oncology Clinics, Specialty Pharmacies, Research Institutions
Lunsumio Market Trends Driving Strategic Industry Expansion
Within the Lunsumio market, a notable development is the adoption of novel strategies such as fixed-duration bispecific antibody therapies, which are designed to improve treatment outcomes and expand patient accessibility. These therapies involve dual-targeting antibodies delivered over a specified, limited time frame instead of through continuous administration, allowing for effective disease management while lessening the prolonged treatment load on patients. A concrete example is the March 2025 launch by Chugai Pharmaceutical, a Japan-based oncology and biotech firm, of LUNSUMIO for Intravenous Infusion (mosunetuzumab), targeted at relapsed or refractory follicular lymphoma. This therapy is given as a standalone treatment for patients who have not responded to at least two prior lines of therapy, employs a predetermined treatment schedule instead of indefinite dosing to mitigate the long-term therapy burden, and aims to deliver elevated complete response rates with the potential for sustained remission in a challenging patient group.
Lunsumio Market Leading Companies Driving Competitive Growth
Major companies operating in the lunsumio market are Roche Holding AG
Access The Complete Lunsumio Market Report:
Lunsumio Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the lunsumio market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lunsumio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model